Workflow
医用生物材料
icon
Search documents
蒋伟被证监会处罚,系这家百亿巨头实控人之一,还是富豪榜常客!公司回应:涉及事项与公司无关!
Sou Hu Cai Jing· 2025-09-17 10:28
Core Viewpoint - The recent penalty imposed on Jiang Wei is personal and unrelated to Haohai Biological Technology Co., Ltd, which he founded but has not actively managed for years [1][4]. Group 1: Company Background - Haohai Biological Technology is a high-tech biopharmaceutical company focused on the research, production, and sales of medical biomaterials, notably hyaluronic acid [4]. - The company was established from Haohai Limited, which Jiang Wei founded, and entered the hyaluronic acid sector in May 2007 [4]. - Hou Yongtai has been the chairman since 2009, while Jiang Wei has remained in the background without any official role in the company [4]. Group 2: Financial Performance - Since its listing in 2019, Haohai Biological has shown a general upward trend in performance, with revenue increasing from 1.6 billion yuan in 2019 to an expected 2.7 billion yuan in 2024 [4]. - The net profit attributable to shareholders has consistently exceeded 200 million yuan, reaching a projected 420 million yuan in 2024, marking a record high since its IPO [4]. - The company has distributed a total of 890 million yuan in cash dividends since its A-share listing, with Jiang Wei personally receiving approximately 254 million yuan from these dividends [4]. Group 3: Shareholding Structure - Jiang Wei and his wife collectively held a significant portion of Haohai Biological's shares, with their ownership percentage increasing from 41.18% to 45.82% over the years [4]. - This shareholding structure indicates that approximately 40% of the total dividends distributed, amounting to 890 million yuan, were allocated to Jiang Wei and his wife [4]. Group 4: Wealth Status - In 2020, Jiang Wei and his wife first appeared on the Hurun Global Rich List with a wealth of 7 billion yuan, maintaining a position on the list for five consecutive years [5]. - As of March 27, 2023, they were ranked 3206th on the Hurun Global Rich List with a wealth of 7.3 billion yuan [5]. - Despite the dividends, Jiang Wei has not benefited significantly from stock market fluctuations, with the company's market value dropping from 15.5 billion yuan at its IPO to 11.55 billion yuan as of September 16, 2023 [5].
26.98亿!昊海生科发布最新年报
思宇MedTech· 2025-03-24 03:42
合作伙伴征集:2025全球手术机器人大会 报名:首届全球骨科大会 | 奖项评选 2025年3月22日, 昊海生科 发布了2024年年报。 # 财报数据 # 关于昊海生科 报名:首届全球眼科大会 | 名额有限 报名:首届全球心血管大会 | 奖项申报 2024年营业收入 26.98亿 元,同比增长1.64%; 归母净利润4.20亿元,同比增长1.04%;扣非归母净 利润3.79亿元,同比下滑1.12%。 2024Q4营业收入 6.23亿 元,同比下滑7.35%,环比增长9.74%; 归母净利润0.80亿元,同比下降 10.93%;扣非归母净利润0.58亿元,同比下滑26.83%。 分产品:2024年医疗美容与创面护理产品收入11.95亿元,同比增长13.08%,其中玻尿酸产品收入 7.42亿元,同比增长23.23%;眼科产品收入8.58亿元,同比下降7.60%;骨科产品收入4.57亿元,同 比下降4.11%;防粘连及止血产品1.46亿元,同比下降0.58%;其他产品收入0.38亿元,同比增长 1.56%。 2024 年公司整体毛利率为 69.89%,与上年度的 70.46%相比略有下降,其中,医美玻尿酸产品收入 ...
26.98亿!昊海生科2024年度业绩快报
思宇MedTech· 2025-03-13 03:59
2024年,昊海生科 实现营业总收入 26.98亿 元 ,较上年同期的26.54亿元增长了1.64%。 这一增长主要得 益于公司在主营业务领域的持续拓展以及市场需求的稳定支撑。 合作伙伴征集:2025全球手术机器人大会 报名:首届全球眼科大会 | 暂定议程 报名:首届全球心血管大会 | 奖项报名倒计时 报名:首届全球骨科大会 | 奖项报名倒计时 近日, 昊海生科 发布了2024年度业绩快报, 公司在过去一年的经营表现整体较为平稳。 # 财务数据 在净利润方面,公司2024年 归属于母公司股东的净利润达到 4.20亿 元 ,较上年同期的4.16亿元增长了 0.97%。尽管净利润实现了正增长,但增速相对较低,显示出公司在盈利增长方面面临一定的压力。与此同 时,公司2024年归属于母公司股东的扣除非经常性损益的净利润为3.81亿元,较上年同期的3.83亿元略有下 降,降幅为0.57%。这表明公司在核心业务的盈利能力上可能受到一定挑战,非经常性损益项目对整体净利 润的影响较为显著。 从财务指标来看,公司2024年的基本每股收益为1.80元,较上年同期的1.75元增长了2.86%。加权平均净资 产收益率为7.41%,较 ...